This is Genzyme Corporation's Summary Annual Report. We have included more detailed information about our business, including financial statements, in the Annual Report on Form 10-K that we filed with the SEC on February 29, 2008. We encourage you to read the Annual Report on Form 10-K and qualify the information in this Summary Annual Report by reference to that filing. For a full printed copy of the Annual Report on Form 10-K, please download and print the on-line pdf file or email Genzyme . For current press releases, please visit the investors section of www.genzyme.com.
This Summary Annual Report contains forward-looking statements regarding our financial outlook and business plans and strategies including, without limitation, our: anticipated compound average earnings growth rate from 2006-2011; 2008 and 2011 EPS guidance; projected revenue growth through 2012; plans and estimated timetables for seeking regulatory approvals and launching existing products for use in new indications, territories or formulations, including Renvela for CKD patients not on dialysis, Renvela powder, Clolar, alemtuzumab-MS, Thymoglobulin, and MACI and the assessment of the market potential of such therapies; plans and estimated timetables for new and next-generation product filings, approvals and launches, including for Mozobil, mipomersen, Synvisc-One, hylastan, and SepraSpray and the assessment of the market potential of such therapies; and our manufacturing plans and timetables. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties including, among others, our ability to: successfully complete preclinical and clinical development of our products and product candidates, including Mozobil, alemtuzumab-MS, and mipomersen ; expand the use of current and next-generation products, including Synvisc-One and Renvela; obtain and maintain regulatory approvals for products and manufacturing facilities, including the larger-scale production of Myozyme and the timing of receipt of such approvals; manufacture products and product candidates in a timely and cost effective manner and in sufficient quantities to meet demand; maintain and enforce our intellectual property rights; successfully identify and market to new patients; secure adequate third-party reimbursement coverage for our products and services; and the risks and uncertainties described in our reports filed with the SEC under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the period ended December 31, 2007. We caution investors not to place substantial reliance on the forward-looking statements contained in this report. These statements speak only as of March 31, 2008 (except financial guidance which was last updated February 13, 2008) and we undertake no obligation to update or revise the statements. In addition, you should read individual statements appearing in our SEC filings with and in the context of the complete documents in which they appear, and any materials incorporated into those documents by reference, rather than as stand-alone documents.
Genzyme®, Cerezyme®, Fabrazyme®, Myozyme®, Renagel®, Renvela®, Hectorol®, Synvisc®, Seprafilm®, SepraSpray®, Carticel®, MACI®, Epicel®, Campath®, MabCampath®, Clolar®, Evoltra®, Thyrogen®, Thymoglobulin® are registered trademarks of and Mozobil™ and Synvisc-One™ are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.
Links:
ANNUAL REPORT HOME
LEGAL DISCLAIMER
